ABSTRACT Objective: To evaluate the cost-utility of latanoprostene bunod 0.024% as first-line therapy compared to the strategy recommended by the Clinical Protocol and Therapeutic Guidelines for primary open-angle glaucoma of the Brazilian Unified Health System. Methods: A cost-utility analysis was conducted using a hypothetical cohort and a Markov model. In the base-case scenario, the treatment strategy recommended by the Clinical Protocol and Therapeutic Guidelines was adopted, initiating therapy with timolol 0.5%. If the target intraocular pressure was not achieved, dorzolamide […]

Objective: To determine the most cost-effective strategy for the treatment of early-stage primary open-angle glaucoma, by comparing the following alternatives: observation, medical therapy or laser treatment. Methods: Using a Markov model, from the perspective of the Brazilian Public Health System (SUS) and a horizon of the average life expectancy of the Brazilian population, we compared the incremental cost-utility ratio (ICUR) among the three treatment alternatives, as well as their costs and the gain in quality of life as measured in […]

PURPOSE:To assess the 5-year cost, effectiveness and costeffectiveness of fixed combinations of prostaglandin or prostamide and timolol 0. 5% on glaucoma and/or ocular hypertension in the state of Minas Gerais, Brazil. METHODS: This cross-sectional study evaluated the following fixed combinations: bimatoprost/timolol 0. 5% (BT), latanoprost/timolol 0. 5% (LT) and travoprost/ timolol 0. 5% (TT). Cost was obtained through mean number of drops in a sample of 5 containers of each medication, duration (days) and the average wholesale price (AWP). Effectiveness […]